Intravenous Neonatal Central Access Safety Trial
Launched by UNIVERSITY OF TURIN, ITALY · Sep 9, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Intravenous Neonatal Central Access Safety Trial is a study looking at the safety of using special filters in the IV lines of newborns in the neonatal intensive care unit (NICU). These filters are designed to catch tiny particles that could potentially harm infants when they receive medications or nutrition through an IV. By using these filters, the trial aims to see if they can help reduce infections and other complications in critically ill infants who need these treatments.
To participate in the trial, babies must be admitted to the NICU and have a central venous catheter, which is a type of IV line placed in a large vein. Unfortunately, babies with a simpler IV line or those experiencing certain health issues at the time of enrollment cannot join. Families can expect that the study will involve monitoring their baby's health while using these filters, helping researchers understand if they truly make a difference in keeping newborns safer during their care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients admitted to NICU with at least one central venous catheter
- Exclusion Criteria:
- • Patients with peripheral venous catheter, patients with inflammatory episode at the time of enrollment
About University Of Turin, Italy
The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Torino, Italia, Italy
Patients applied
Trial Officials
Francesco Cresi, PhD MD
Study Director
University of Turin, Italy
Alessandra Coscia, PhD MD
Study Director
University of Turin, Italy
Elena Maggiora, MD
Principal Investigator
University of Turin, Italy
Cecilia Capetti, MD
Principal Investigator
University of Turin, Italy
Francesca De Matteis, RN
Principal Investigator
Città della salute e della Scienza di Torino
Martina Capitanio, MD
Principal Investigator
University of Turin, Italy
Fabio Mosca, Prof.
Study Chair
University of Milan, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials